Comparing the current results to its competitors, Champions Oncology Inc reported Revenue increase in the 4 quarter 2026 by 11.99 % year on year, while most of its competitors have experienced contraction in revenues by -40.77 %, achieved in the same quarter.
Champions Oncology Inc 's Comment on Competition and Industry Peers
Competition Champions operates in three markets, including Research Services and SaaS. In Research Services, the company competes with other healthcare companies in the United States and internationally, many of which are larger and have more resources and longer operating histories. Competitors also include academic institutions, governmental agencies, and private research organizations, all of which compete for scientific, technical, and professional personnel. In the SaaS market, Competition Champions offers its Datacenter product, which it considers unique; however, the availability of numerous publicly accessible datasets for computational research presents competitive challenges.
Company's competitiveness improved within Overall company, with revenue growth of 11.99 % and its market share increased to approx. 15.19 %. << More on CSBR Market Share.
*Market share is calculated based on total revenue.
Cellectis S is a biotechnology company that operates using a business model focused on developing and commercializing gene editing technologies. They utilize a proprietary platform called TALEN® to modify genes for various applications in agriculture, healthcare, and biomanufacturing. By providing innovative solutions through gene editing, Cellectis aims to address critical challenges in these industries and create value for their customers and stakeholders.
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
Adaptive Biotechnologies Corporation is a biotechnology company that utilizes its proprietary immune medicine platform to decode and analyze the human immune system. Their business model focuses on providing solutions for the diagnosis, monitoring, and treatment of various diseases such as cancer and infectious diseases. By leveraging genomics and machine learning technologies, they aim to create personalized immunotherapies and diagnostics to improve patient outcomes.
Sensei Biotherapeutics Inc is a biotechnology company that focuses on developing personalized and targeted cancer therapies. They employ a unique approach called ImmunoPhage, which utilizes bacteriophages to specifically target tumor antigens and stimulate an immune response. Their business model revolves around conducting research and clinical trials to bring innovative cancer treatment options to market.
Vista Energy S a b De C v operates as a business-to-business company in the energy sector. Their business model involves supplying energy solutions to commercial and industrial clients, focusing on renewable energy sources and energy efficiency. They tailor their services to meet specific client needs, providing cost-effective and sustainable energy solutions.
Sources:
Champions Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Champions Oncology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
